Strain Name:

B6;129-Dbhtm2(Th)Rpa Thtm1Rpa/J

Stock Number:

009688

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Use Restrictions Apply, see Terms of Use
Dopamine-deficient (DA-deficient, DA-/-, or DD) mice are homozygous for the TH mutant allele and heterozygous for the DBH-TH mutant allele (Th-/-;DbhTh/+). While no expression from the TH mutant allele is observed in any tissues (resulting in deficiency of both dopamine (DA) and norepinephrine (NE)), the DBH-TH mutant allele contains the TH coding sequence under the control of the endogenous DBH promoter region and restores TH expression in noradrenergic neurons. These DD mice may be useful in studying dopaminergic neurobiology (including neurotransmitters, addiction, feeding, learning and memory, catecholamines, and Parkinsonian phenotypes).

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Mutant Stock; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
Generation?+N1F1pN1
Generation Definitions
 
Donating Investigator Claire Cannon,   Marquette University

Important Note
Dopamine-deficient (DA-deficient, DA-/-, or DD) mice are homozygous for the TH mutant allele and heterozygous for the DBH-TH mutant allele (Th-/-; DbhTh/+). When maintained as congenic on a C57BL/6 genetic background, Th-/-; DbhTh/+ mice may exhibit declining birth rates and increased mortality (Hnasko et al 2007 J Neurosci 27:12484-8). Therefore, the colony at The Jackson Laboratory is maintained as heterozygous for both mutant alleles.

Description
Mice heterozygous for both targeted mutations are viable and fertile. Dopamine-deficient (DA-deficient, DA-/-, or DD) mice are homozygous for the TH mutant allele and heterozygous for the DBH-TH mutant allele (Th-/-; DbhTh/+). While no expression from the TH mutant allele is observed in any tissues (resulting in deficiency of both dopamine (DA) and norepinephrine (NE)), the DBH-TH mutant allele contains the TH coding sequence under the control of the endogenous DBH promoter region and restores TH expression in noradrenergic neurons. DD mice become hypoactive and hypophagic around two weeks of age and usually die before four weeks of age. Treatment with L-DOPA, the product of TH enzymatic activity, rescues size, feeding, and life span. These DD mice may be useful in studying dopaminergic neurobiology (including neurotransmitters, addiction, feeding, learning and memory, catecholamines, and Parkinsonian phenotypes).

NOTE: Th-/-; DbhTh/+ mice congenic on a C57BL/6 genetic background may exhibit declining birth rates and increased mortality (Hnasko et al 2007 J Neurosci 27:12484-8).

Development
To generate the TH knockout allele , the pTH4 targeting vector was designed to replace the proximal promoter and first two exons of the Th locus with a PGK-neomycin resistance cassette. The construct was electroporated into 129S7/SvEvBrd-Hprt1+ derived AB1 embryonic stem (ES) cells. Correctly targeted ES cells were injected into recipient blastocysts and the resulting heterozygous mice were maintained on a C57BL/6/129S hybrid background.
To generate the DBH-TH mutant allele (DbhTh), the pDBH-TH vector was designed to insert the entire mouse Th coding region (including 1 kb sequence after the polyA site) and a neo cassette between exons 1 and 2 of the Dbh locus. The construct was electroporated into unspecified embryonic stem (ES) cells and heterozygous animals were obtained.
Next, mice heterozygous for the TH mutant allele (Th-/+) were bred with mice heterozygous for the DBH-TH mutant allele (DbhTh/+). The donating investigator reports that double mutant mice were subsequently backcrossed to C57BL/6J mice for several (9-14) generations prior to arrival at The Jackson Laboratory. Upon arrival, mutant mice were bred with C57BL/6J inbred mice (Stock No. 000664) for at least one generation to establish the colony.

A 27 SNP (single nucleotide polymorphism) panel analysis performed by The Jackson Laboratory revealed the mice to be ~85% C57BL/6 genetic background; 4 of 27 markers were segregating for C57BL/6 or 129S allele-type markers (on chromosomes 2, 3, 8 and 11). These data suggest that, prior to arrival at the Jackson Laboratory, the mice were not backcrossed to C57BL/6 for as many generations as originally reported.

Control Information

  Control
   101043 B6129SF1/J (approximate)
   101045 B6129SF2/J (approximate)
   000664 C57BL/6J (approximate)
 
  Considerations for Choosing Controls

Related Strains

Parkinson's Disease Models
005987   129-Achetm1Loc/J
007587   129S-Park2tm1Rpa/J
002779   129S-Parp1tm1Zqw/J
017001   129S.B6N-Plk2tm1Elan/J
016198   129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ
004608   B6(Cg)-Htra2mnd2/J
021828   B6(SJL)-Lrrk2tm3.1Mjff/J
008133   B6.129-Sncbtm1Sud/J
008084   B6.129P2-Drd4tm1Dkg/J
004744   B6.129P2-Esr1tm1Ksk/J
013586   B6.129P2-Gt(ROSA)26Sortm1Nik/J
002609   B6.129P2-Nos2tm1Lau/J
008843   B6.129P2-Sncgtm1Vlb/J
016566   B6.129S-Hcn1tm2Kndl/J
004322   B6.129S1-Mapk10tm1Flv/J
003190   B6.129S2-Drd2tm1Low/J
006582   B6.129S4-Park2tm1Shn/J
017946   B6.129S4-Pink1tm1Shn/J
005934   B6.129S4-Ucp2tm1Lowl/J
004936   B6.129S6(Cg)-Spp1tm1Blh/J
012453   B6.129X1(FVB)-Lrrk2tm1.1Cai/J
017009   B6.129X1-Nfe2l2tm1Ywk/J
009346   B6.Cg-Lrrk2tm1.1Shn/J
005491   B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
006577   B6.Cg-Park7tm1Shn/J
000567   B6.Cg-T2J +/+ Qkqk-v/J
007004   B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ
003139   B6.Cg-Tg(DBHn-lacZ)8Rpk/J
007673   B6.Cg-Tg(Gad1-EGFP)3Gfng/J
012466   B6.Cg-Tg(Lrrk2)6Yue/J
012467   B6.Cg-Tg(Lrrk2*G2019S)2Yue/J
008323   B6.Cg-Tg(Mc4r-MAPT/Sapphire)21Rck/J
008321   B6.Cg-Tg(Npy-MAPT/Sapphire)1Rck/J
008324   B6.Cg-Tg(Pmch-MAPT/CFP)1Rck/J
008322   B6.Cg-Tg(Pomc-MAPT/Topaz)1Rck/J
007894   B6.Cg-Tg(Rgs4-EGFP)4Lvt/J
012588   B6.Cg-Tg(TH-ALPP)1Erav/J
012265   B6.Cg-Tg(THY1-SNCA*A30P)TS2Sud/J
008859   B6.Cg-Tg(THY1-SNCA*A53T)F53Sud/J
008135   B6.Cg-Tg(THY1-SNCA*A53T)M53Sud/J
008601   B6.Cg-Tg(Th-cre)1Tmd/J
013583   B6.Cg-Tg(tetO-LRRK2)C7874Cai/J
000544   B6.D2-Cacna1atg/J
012445   B6.FVB-Tg(LRRK2)WT1Mjfa/J
012446   B6.FVB-Tg(LRRK2*G2019S)1Mjfa/J
006660   B6.SJL-Slc6a3tm1.1(cre)Bkmn/J
008364   B6;129-Chattm1(cre/ERT)Nat/J
008883   B6;129-Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/TmdJ
008889   B6;129-Gt(ROSA)26Sortm2(SNCA*119)Djmo/TmdJ
008886   B6;129-Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/TmdJ
009347   B6;129-Lrrk2tm1.1Shn/J
016209   B6;129-Lrrk2tm2.1Shn/J
016210   B6;129-Lrrk2tm3.1Shn/J
013050   B6;129-Pink1tm1Aub/J
004807   B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax
006390   B6;129-Sncatm1Sud Sncbtm1.1Sud/J
008532   B6;129-Thtm1(cre/Esr1)Nat/J
008333   B6;129P2-Dldtm1Ptl/J
008333   B6;129P2-Dldtm1Ptl/J
002596   B6;129P2-Nos2tm1Lau/J
003243   B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J
003692   B6;129X1-Sncatm1Rosl/J
016575   B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J
016576   B6;C3-Tg(PDGFB-LRRK2*R1441C)574Djmo/J
008169   B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J
004479   B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J
000231   B6;C3Fe a/a-Csf1op/J
012450   B6;D2-Tg(tetO-SNCA)1Cai/J
013725   B6;SJL-Tg(LRRK2)66Mjff/J
008473   B6;SJL-Tg(THY1-SNCA*A30P)M30Sud/J
008134   B6;SJL-Tg(THY1-SNCA*A30P)TS2Sud/J
016976   B6C3-Tg(tetO-SNCA*A53T)33Vle/J
000506   B6C3Fe a/a-Qkqk-v/J
003741   B6D2-Tg(Prnp-MAPT)43Vle/J
024841   B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J
018768   B6N.Cg-Tg(SNCA*E46K)3Elan/J
012621   C.129S(B6)-Chrna3tm1.1Hwrt/J
016120   C57BL/6-Lrrk1tm1.1Mjff/J
012444   C57BL/6-Lrrk2tm1Mjfa/J
008389   C57BL/6-Tg(THY1-SNCA)1Sud/J
012769   C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
018785   C57BL/6J-Tg(LRRK2*G2019S)2AMjff/J
018786   C57BL/6J-Tg(LRRK2*R1441G)3IMjff/J
008245   C57BL/6J-Tg(Th-SNCA)5Eric/J
008239   C57BL/6J-Tg(Th-SNCA*A30P*A53T)39Eric/J
016122   C57BL/6N-Lrrk1tm1.1Mjff Lrrk2tm1.1Mjff/J
016121   C57BL/6N-Lrrk2tm1.1Mjff/J
016123   C57BL/6N-Sncatm1Mjff/J
016936   C57BL/6N-Tg(Thy1-SNCA)12Mjff/J
017682   C57BL/6N-Tg(Thy1-SNCA)15Mjff/J
007677   CB6-Tg(Gad1-EGFP)G42Zjh/J
009610   FVB/N-Tg(LRRK2)1Cjli/J
009609   FVB/N-Tg(LRRK2*G2019S)1Cjli/J
009604   FVB/N-Tg(LRRK2*R1441G)135Cjli/J
009090   FVB/NJ-Tg(Slc6a3-PARK2*Q311X)AXwy/J
017678   FVB;129-Pink1tm1Aub Tg(Prnp-SNCA*A53T)AAub/J
017744   FVB;129-Tg(Prnp-SNCA*A53T)AAub/J
010710   FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J
010788   FVB;129S6-Sncatm1Nbm Tg(SNCA*A30P)1Nbm Tg(SNCA*A30P)2Nbm/J
010799   FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J
004808   STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
000942   STOCK Pitx3ak/2J
014092   STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J
006340   STOCK Tg(Gad1-EGFP)98Agmo/J
017000   STOCK Tg(SNCA*E46K)3Elan/J
008474   STOCK Tg(THY1-SNCA*A53T)F53Sud/J
008132   STOCK Tg(THY1-Snca)M1mSud/J
012441   STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J
012442   STOCK Tg(tetO-SNCA*A53T)E2Cai/J
012449   STOCK Tg(teto-LRRK2)C7874Cai/J
View Parkinson's Disease Models     (112 strains)

Strains carrying other alleles of Th
008532   B6;129-Thtm1(cre/Esr1)Nat/J
008779   STOCK Thtm1Srt/J
View Strains carrying other alleles of Th     (2 strains)

Additional Web Information

Visit the Parkinson's Disease Resource site for helpful information on Parkinson's and research resources.

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Dopamine Beta-Hydroxylase Deficiency, Congenital   (DBH)
Segawa Syndrome, Autosomal Recessive   (TH)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Dbhtm2(Th)Rpa/Dbh+ Thtm1Rpa/Thtm1Rpa

        involves: 129S7/SvEvBrd * C57BL/6J
  • mortality/aging
  • premature death
    • can be maintained for at least 1.5 years with daily treatment of 50 mg/kg L-DOPA and feeding with breeder chow (4.35 kcal/g)   (MGI Ref ID J:58125)
  • behavior/neurological phenotype
  • abnormal gait
    • 24 or more hours after L-DOPA treatment the gait is awkward   (MGI Ref ID J:58125)
  • akinesia
    • 24 hours after L-DOPA treatment 1- and 4-limb akinesia is increased compared to controls   (MGI Ref ID J:58125)
  • catalepsy
    • 24 hours after L-DOPA treatment forelimb catalepsy is increased compared to controls   (MGI Ref ID J:58125)
  • decreased food intake
    • during the first 24 hours after L-DOPA treatment food intake is similar to controls but during the next 24 hours intake decreases to about 10% of wild-type   (MGI Ref ID J:58125)
    • food intake is proportional to L-DOPA dose up to 100 mg/kg   (MGI Ref ID J:58125)
    • decreased compensatory feeding amount
      • if food is with held for 3 or 6 hours after L-DOPA treatment mice compensate by consuming more food in the next 3 hours to consume about the same amount of food as when food is continually available; however no compensation if food is with held for 9 hours   (MGI Ref ID J:58125)
      • after a 30 hour fast when presented with a high sucrose, high-fat diet mice begin to consume food but cease eating sooner and consume only about 25% of the amount eaten by wild-type mice   (MGI Ref ID J:58125)
  • hunched posture   (MGI Ref ID J:58125)
  • hyperactivity
    • for 6 - 9 hours after L-DOPA treatment activity level is higher than in wild-type   (MGI Ref ID J:58125)
    • treatment with L-DOPA and carbidopa induces a biphasic increase in activity that is more prolonged than when L-DOPA is given alone; however, in wild-type mice L-DOPA and carbidopa treatment induces inactivity   (MGI Ref ID J:58125)
  • hypoactivity
    • in untreated mice or by 24 hours after L-DOPA treatment   (MGI Ref ID J:58125)
    • a second small peak of activity occurs between 24 and 40 hours after treatment however overall activity is decreased compared to controls   (MGI Ref ID J:58125)
  • hyporesponsive to tactile stimuli
    • 1 hour after L-DOPA treatment a decrease in response in the paw pinch assay is seen   (MGI Ref ID J:58125)
  • impaired behavioral response to addictive substance
    • 19 hours after L-DOPA treatment a single dose of amphetamine (5mg/kg) induces a shorter increase in activity (1 hour compared to 2 hours in controls) and a second dose of amphetamine fails to alter activity unlike in controls   (MGI Ref ID J:58125)
  • impaired coordination
    • 24 or more hours after L-DOPA treatment rotarod and pole test performance are poor   (MGI Ref ID J:58125)
  • increased stereotypic behavior
    • treatment with L-DOPA and carbidopa induces intense stereotypic behavior (licking and chewing of paws) between 1 and 5 hours after treatment, no such behavior is seen in controls   (MGI Ref ID J:58125)
  • integument phenotype
  • hyporesponsive to tactile stimuli
    • 1 hour after L-DOPA treatment a decrease in response in the paw pinch assay is seen   (MGI Ref ID J:58125)

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Dbhtm2(Th)Rpa/Dbh+ Thtm1Rpa/Thtm1Rpa

        involves: 129S7/SvEvBrd
  • mortality/aging
  • premature death
    • all die by 4 weeks of age   (MGI Ref ID J:30404)
    • twice daily treatment with 50 mg/kg L-dihydroxyphenylalanine (L-DOPA) starting around P15 rescues the lethality   (MGI Ref ID J:30404)
  • growth/size/body phenotype
  • decreased body size
    • at P10 - P15   (MGI Ref ID J:30404)
    • decreased body weight
      • at P16, body weight is 70% of control littermates   (MGI Ref ID J:30404)
      • weight loss
        • after P17 a negative growth rate is seen   (MGI Ref ID J:30404)
        • twice daily treatment with 50 mg/kg L-DOPA starting around P15 restores a nearly normal growth rate   (MGI Ref ID J:30404)
  • behavior/neurological phenotype
  • adipsia
    • injection with L-DOPA restores drinking behavior   (MGI Ref ID J:30404)
  • aphagia
    • injection with L-DOPA restores eating behavior with maximal intake during the first 2 hours after injection and cessation of eating by about 6 hours post injection   (MGI Ref ID J:30404)
  • decreased stereotypic behavior
    • make about 280 stereotypical beam breaks per hour compared to about 700 per hour for controls   (MGI Ref ID J:30404)
  • hunched posture
    • at P10 - P15   (MGI Ref ID J:30404)
  • hypoactivity
    • at P10 - P15, travel only about 3m/hr compared to 23 m/hr in controls   (MGI Ref ID J:30404)
    • however at P16, reflexion, corneal, startle, righting, grasping, and placing reflexes are all similar to controls, balance is not impaired, and no tremors are seen   (MGI Ref ID J:30404)
    • within 15 minutes of injection of L-DOPA activity levels increase peaking at about 1 hour post injection and then decreasing so that by 12 hours post injection mice are hypoactive   (MGI Ref ID J:30404)
  • poor grooming
    • at P10 - P15   (MGI Ref ID J:30404)
  • nervous system phenotype
  • abnormal nervous system physiology
    • expression levels of tachykinin 1 and dynorphin are decreased in the striatum   (MGI Ref ID J:30404)
    • decreased dopamine level
      • dopamine levels in the brain are low; however, levels of norepinephrine in the brain, heart, salivary glands, and adrenal glands are similar to controls   (MGI Ref ID J:30404)
  • decreased brain size
    • brain size is reduced and neurons are slightly more compact; however, dopaminergic neuron and striatum morphology are similar to controls   (MGI Ref ID J:30404)
  • homeostasis/metabolism phenotype
  • decreased dopamine level
    • dopamine levels in the brain are low; however, levels of norepinephrine in the brain, heart, salivary glands, and adrenal glands are similar to controls   (MGI Ref ID J:30404)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Developmental Biology Research
Perinatal Lethality

Neurobiology Research
Behavioral and Learning Defects
Neurotransmitter Receptor and Synaptic Vesicle Defects
Parkinson's Disease
Response to Catecholamines

Research Tools
Toxicology Research
      drug metabolism
      drug/compound testing

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Dbhtm2(Th)Rpa
Allele Name targeted mutation 2, Richard D Palmiter
Allele Type Targeted
Common Name(s) DBH-TH-; DbhTh;
Expressed Gene Th, tyrosine hydroxylase, mouse, laboratory
Molecular Note The entire Th coding region, including 1kb sequence after the polyadenylation site and a neomycin resistance cassette, was inserted between exons 1 and 2 of the Dbh gene. [MGI Ref ID J:30404]
 
Gene Symbol and Name Dbh, dopamine beta hydroxylase
Chromosome 2
Gene Common Name(s) DBM; DOPBHY;
 
Allele Symbol Thtm1Rpa
Allele Name targeted mutation 1, Richard D Palmiter
Allele Type Targeted (Null/Knockout)
Common Name(s) DA-; TH-; pTH4;
Strain of Origin129S7/SvEvBrd-Hprt<+>
ES Cell Line NameAB1
ES Cell Line Strain129S7/SvEvBrd-Hprt<+>
Molecular Note A neomycin selection cassette replaced the proximal promoter and exons 1 and 2. [MGI Ref ID J:24347]

Genotyping

Genotyping Information

Genotyping Protocols

Dbhtm2(Th)Rpa MCA, Melt Curve Analysis


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Cannon CM; Palmiter RD. 2003. Reward without dopamine. J Neurosci 23(34):10827-31. [PubMed: 14645475]  [MGI Ref ID J:86847]

Hnasko TS; Sotak BN; Palmiter RD. 2007. Cocaine-conditioned place preference by dopamine-deficient mice is mediated by serotonin. J Neurosci 27(46):12484-8. [PubMed: 18003826]  [MGI Ref ID J:127594]

Szczypka MS; Rainey MA; Kim DS; Alaynick WA; Marck BT; Matsumoto AM; Palmiter RD. 1999. Feeding behavior in dopamine-deficient mice. Proc Natl Acad Sci U S A 96(21):12138-43. [PubMed: 10518589]  [MGI Ref ID J:58125]

Zhou QY; Palmiter RD. 1995. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83(7):1197-209. [PubMed: 8548806]  [MGI Ref ID J:30404]

Additional References

Dbhtm2(Th)Rpa related

Chartoff EH; Marck BT; Matsumoto AM; Dorsa DM; Palmiter RD. 2001. Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc Natl Acad Sci U S A 98(18):10451-6. [PubMed: 11517332]  [MGI Ref ID J:126668]

Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM. 2004. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy. Brain Res 1022(1-2):71-80. [PubMed: 15353215]  [MGI Ref ID J:92531]

Denenberg VH; Kim DS; Palmiter RD. 2004. The role of dopamine in learning, memory, and performance of a water escape task. Behav Brain Res 148(1-2):73-8. [PubMed: 14684249]  [MGI Ref ID J:87763]

Fadok JP; Dickerson TM; Palmiter RD. 2009. Dopamine is necessary for cue-dependent fear conditioning. J Neurosci 29(36):11089-97. [PubMed: 19741115]  [MGI Ref ID J:152679]

Hasbani DM; Perez FA; Palmiter RD; O'Malley KL. 2005. Dopamine depletion does not protect against acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in vivo. J Neurosci 25(41):9428-33. [PubMed: 16221852]  [MGI Ref ID J:123449]

Henschen CW; Palmiter RD; Darvas M. 2013. Restoration of dopamine signaling to the dorsal striatum is sufficient for aspects of active maternal behavior in female mice. Endocrinology 154(11):4316-27. [PubMed: 23959937]  [MGI Ref ID J:203835]

Hnasko TS; Perez FA; Scouras AD; Stoll EA; Gale SD; Luquet S; Phillips PE; Kremer EJ; Palmiter RD. 2006. Cre recombinase-mediated restoration of nigrostriatal dopamine in dopamine-deficient mice reverses hypophagia and bradykinesia. Proc Natl Acad Sci U S A 103(23):8858-63. [PubMed: 16723393]  [MGI Ref ID J:110806]

Hnasko TS; Sotak BN; Palmiter RD. 2005. Morphine reward in dopamine-deficient mice. Nature 438(7069):854-7. [PubMed: 16341013]  [MGI Ref ID J:103809]

Hnasko TS; Szczypka MS; Alaynick WA; During MJ; Palmiter RD. 2004. A role for dopamine in feeding responses produced by orexigenic agents. Brain Res 1023(2):309-18. [PubMed: 15374756]  [MGI Ref ID J:92829]

Kim DS; Palmiter RD. 2003. Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice. Proc Natl Acad Sci U S A 100(3):1346-51. [PubMed: 12538862]  [MGI Ref ID J:81841]

Kim DS; Palmiter RD; Cummins A; Gerfen CR. 2006. Reversal of supersensitive striatal dopamine D(1) receptor signaling and extracellular signal-regulated kinase activity in dopamine-deficient mice. Neuroscience 137(4):1381-8. [PubMed: 16388913]  [MGI Ref ID J:105583]

Land BB; Bruchas MR; Schattauer S; Giardino WJ; Aita M; Messinger D; Hnasko TS; Palmiter RD; Chavkin C. 2009. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci U S A 106(45):19168-73. [PubMed: 19864633]  [MGI Ref ID J:154773]

Lemos JC; Wanat MJ; Smith JS; Reyes BA; Hollon NG; Van Bockstaele EJ; Chavkin C; Phillips PE. 2012. Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive. Nature 490(7420):402-6. [PubMed: 22992525]  [MGI Ref ID J:189229]

Paladini CA; Robinson S; Morikawa H; Williams JT; Palmiter RD. 2003. Dopamine controls the firing pattern of dopamine neurons via a network feedback mechanism. Proc Natl Acad Sci U S A 100(5):2866-71. [PubMed: 12604788]  [MGI Ref ID J:82388]

Robinson S; Smith DM; Mizumori SJ; Palmiter RD. 2004. Firing properties of dopamine neurons in freely moving dopamine-deficient mice: effects of dopamine receptor activation and anesthesia. Proc Natl Acad Sci U S A 101(36):13329-34. [PubMed: 15317940]  [MGI Ref ID J:92402]

Seeman P; Weinshenker D; Quirion R; Srivastava LK; Bhardwaj SK; Grandy DK; Premont RT; Sotnikova TD; Boksa P; El-Ghundi M; O'dowd BF; George SR; Perreault ML; Mannisto PT; Robinson S; Palmiter RD; Tallerico T. 2005. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 102(9):3513-8. [PubMed: 15716360]  [MGI Ref ID J:96985]

Sotak BN; Hnasko TS; Robinson S; Kremer EJ; Palmiter RD. 2005. Dysregulation of dopamine signaling in the dorsal striatum inhibits feeding. Brain Res 1061(2):88-96. [PubMed: 16226228]  [MGI Ref ID J:124410]

Szczypka MS; Kwok K; Brot MD; Marck BT; Matsumoto AM; Donahue BA; Palmiter RD. 2001. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron 30(3):819-28. [PubMed: 11430814]  [MGI Ref ID J:70162]

Szczypka MS; Rainey MA; Palmiter RD. 2000. Dopamine is required for hyperphagia in Lep(ob/ob) mice. Nat Genet 25(1):102-4. [PubMed: 10802666]  [MGI Ref ID J:61883]

Thtm1Rpa related

Chartoff EH; Marck BT; Matsumoto AM; Dorsa DM; Palmiter RD. 2001. Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc Natl Acad Sci U S A 98(18):10451-6. [PubMed: 11517332]  [MGI Ref ID J:126668]

Denenberg VH; Kim DS; Palmiter RD. 2004. The role of dopamine in learning, memory, and performance of a water escape task. Behav Brain Res 148(1-2):73-8. [PubMed: 14684249]  [MGI Ref ID J:87763]

Hasbani DM; Perez FA; Palmiter RD; O'Malley KL. 2005. Dopamine depletion does not protect against acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in vivo. J Neurosci 25(41):9428-33. [PubMed: 16221852]  [MGI Ref ID J:123449]

Kim DS; Szczypka MS; Palmiter RD. 2000. Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J Neurosci 20(12):4405-13. [PubMed: 10844009]  [MGI Ref ID J:120532]

Sotak BN; Hnasko TS; Robinson S; Kremer EJ; Palmiter RD. 2005. Dysregulation of dopamine signaling in the dorsal striatum inhibits feeding. Brain Res 1061(2):88-96. [PubMed: 16226228]  [MGI Ref ID J:124410]

Szczypka MS; Rainey MA; Palmiter RD. 2000. Dopamine is required for hyperphagia in Lep(ob/ob) mice. Nat Genet 25(1):102-4. [PubMed: 10802666]  [MGI Ref ID J:61883]

Tsahai Tafari A; Thomas SA; Palmiter RD. 1997. Norepinephrine facilitates the development of the murine sweat response but is not essential. J Neurosci 17(11):4275-81. [PubMed: 9151744]  [MGI Ref ID J:40429]

Zhou QY; Quaife CJ; Palmiter RD. 1995. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 374(6523):640-3. [PubMed: 7715703]  [MGI Ref ID J:24347]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, mice heterozygous for both targeted alleles may be bred together. DD mice (homozygous for the TH mutant allele and heterozygous for the DBH-TH mutant allele; Th-/-;DbhTh/+) become hypoactive and hypophagic around two weeks of age and usually die before 4 weeks of age. Further backcrossing to the C57BL/6 genetic background may result in declining birth rates and increased mortality of DD mice.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2140.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We willfulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2782.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We willfulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Control Information

  Control
   101043 B6129SF1/J (approximate)
   101045 B6129SF2/J (approximate)
   000664 C57BL/6J (approximate)
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Important Note

Dopamine-deficient (DA-deficient, DA-/-, or DD) mice are homozygous for the TH mutant allele and heterozygous for the DBH-TH mutant allele (Th-/-; DbhTh/+). When maintained as congenic on a C57BL/6 genetic background, Th-/-; DbhTh/+ mice may exhibit declining birth rates and increased mortality (Hnasko et al 2007 J Neurosci 27:12484-8). Therefore, the colony at The Jackson Laboratory is maintained as heterozygous for both mutant alleles.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.6)